Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib PK in Chinese women with ER+/HER2- advanced breast cancer
NCT02499146Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at Day 21, Area Under the Concentration-Time Curve at Day 21 and 1 more. Started Sep 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02499146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499146.